

Reconstitution of the complete rupture in musculotendinous junction using skeletal muscle-derived multipotent stem cell sheet-pellets as a “bio-bond”

Hiroyuki Hashimoto, Tetsuro Tamaki, Maki Hirata, Yoshiyasu Uchiyama, Masato Sato, Joji Mochida

Background. Significant and/or complete rupture in the musculotendinous junction (MTJ) is a challenging lesion to treat because of the lack of reliable suture methods. Skeletal muscle-derived multipotent stem cell (Sk-MSC) sheet-pellets, which are able to reconstitute peripheral nerve and muscular/vascular tissues with robust connective tissue networks, have been applied as a “bio-bond”. **Methods.** Sk-MSC sheet-pellets, derived from GFP transgenic-mice after 7 days of expansion culture, were detached with EDTA to maintain cell-cell connections. A completely ruptured MTJ model was prepared in the right tibialis anterior (TA) of the recipient mice, and was covered with sheet-pellets. The left side was preserved as a contralateral control. The control group received the same amount of the cell-free medium. The sheet-pellet transplantation (SP) group was further divided into two groups; as the short term (4-8 weeks) and long term (14-18 weeks) recovery group. At each time point after transplantation, tetanic tension output was measured through the electrical stimulation of the sciatic nerve. The behavior of engrafted GFP⁺ tissues and cells was analyzed by fluorescence immunohistochemistry. **Results.** The SP short term recovery group showed average 64% recovery of muscle mass, and 36% recovery of tetanic tension output relative to the contralateral side. Then, the SP long term recovery group showed increased recovery of average muscle mass (77%) and tetanic tension output (49%). However, the control group showed no recovery of continuity between muscle and tendon, and demonstrated increased muscle atrophy, with coalescence to the tibia during 4-8 weeks after operation. Histological evidence also supported the above functional recovery of SP group. Engrafted Sk-MSCs primarily formed the connective tissues and muscle fibers, including nerve-vascular networks, and bridged the ruptured tendon-muscle fiber units, with differentiation into skeletal muscle cells, Schwann cells, vascular smooth muscle, and endothelial cells. **Discussion.** This bridging capacity between tendon and muscle fibers of the Sk-MSC sheet-pellet, as a “bio-bond”, represents a possible treatment for various MTJ ruptures following surgery.

1 **Reconstitution of the complete rupture in musculotendinous**
2 **junction using skeletal muscle-derived multipotent stem cell sheet-**
3 **pellets as a “bio-bond”**

4 **Hiroyuki Hashimoto^{1,2}, Tetsuro Tamaki^{2,3}, Maki Hirata^{1,2}, Yoshiyasu Uchiyama^{1,2}, Masato**
5 **Sato¹, Joji Mochida¹.**

6 ¹Department of Orthopedics,

7 ²Muscle Physiology and Cell Biology Unit,

8 ³Department of Human Structure and Function,

9 Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193 Japan.

10 **Correspondence to:** Tetsuro Tamaki, PhD

11 Muscle Physiology and Cell Biology Unit, Department of Human structure and Function, Tokai

12 University School of Medicine

13 143-Shimokasuya, Isehara, Kanagawa 259-1143 Japan.

14 Tel: +81-463-93-1121 (ext.2524); Fax: +81+463-95-0961

15 E-mail: tamaki@is.icc.u-tokai.ac.jp

16 **ABSTRACT**

17 **Background.** Significant and/or complete rupture in the musculotendinous junction (MTJ) is a
18 challenging lesion to treat because of the lack of reliable suture methods. Skeletal muscle-derived
19 multipotent stem cell (Sk-MSC) sheet-pellets, which are able to reconstitute peripheral nerve and
20 muscular/vascular tissues with robust connective tissue networks, have been applied as a “bio-
21 bond”.

22 **Methods.** Sk-MSC sheet-pellets, derived from GFP transgenic-mice after 7 days of expansion
23 culture, were detached with EDTA to maintain cell-cell connections. A completely ruptured MTJ
24 model was prepared in the right tibialis anterior (TA) of the recipient mice, and was covered with
25 sheet-pellets. The left side was preserved as a contralateral control. The control group received
26 the same amount of the cell-free medium. The sheet-pellet transplantation (SP) group was further
27 divided into two groups; as the short term (4-8 weeks) and long term (14-18 weeks) recovery
28 group. At each time point after transplantation, tetanic tension output was measured through the
29 electrical stimulation of the sciatic nerve. The behavior of engrafted GFP⁺ tissues and cells was
30 analyzed by fluorescence immunohistochemistry.

31 **Results.** The SP short term recovery group showed average 64% recovery of muscle mass, and
32 36% recovery of tetanic tension output relative to the contralateral side. Then, the SP long term
33 recovery group showed increased recovery of average muscle mass (77%) and tetanic tension
34 output (49%). However, the control group showed no recovery of continuity between muscle and
35 tendon, and demonstrated increased muscle atrophy, with coalescence to the tibia during 4-8
36 weeks after operation. Histological evidence also supported the above functional recovery of SP
37 group. Engrafted Sk-MSCs primarily formed the connective tissues and muscle fibers, including
38 nerve-vascular networks, and bridged the ruptured tendon-muscle fiber units, with differentiation

39 into skeletal muscle cells, Schwann cells, vascular smooth muscle, and endothelial cells.

40 **Discussion.** This bridging capacity between tendon and muscle fibers of the Sk-MSC sheet-
41 pellet, as a “bio-bond”, represents a possible treatment for various MTJ ruptures following
42 surgery.

43 **Key words:** nerve reconstitution, vascular reconstitution, muscle regeneration, tendon
44 regeneration, stem cell therapy.

45 INTRODUCTION

46 Skeletal muscles represent muscle-tendon complexes attached to the bone. However, due
47 to their roles in the protection of the body and the force generation at the body-movements,
48 injuries invariably occur during various activities or as a result of accidents. Muscle injuries can
49 be classified as ruptures, tears, and lacerations, typically caused by external hard compression
50 (contusion) or excessive stretching forces, and they are categorized into 3 grades of severity, as
51 follows: Grade-I (mild) injury affects only a limited number of fibers in the muscle, and the
52 strength does not decrease in the full active and passive range of motions, with pain and
53 tenderness being delayed until the next day; Grade-II (moderate) injury, where nearly half of
54 muscle fibers are torn, and acute and significant pain is accompanied by swelling and a minor
55 decrease in muscle strength; Grade-III (severe) injury, with the complete rupture of the muscle,
56 where the injured muscle is torn into 2 parts, together with severe swelling and pain, and a total
57 loss of function. The injuries can be broadly divided according to their location in the muscle
58 belly, musculotendinous junction (MTJ), and tendon tear (Chan et al. 2012; ElMaraghy &
59 Devereaux 2012). Generally, for Grade-I and -II injuries, conservative treatments are usually
60 applied, but in the case of Grade-III injuries, surgical intervention is often considered (Kragh et
61 al. 2005c; Oliva et al. 2013; Rawson et al. 2013). Several suturing techniques have been reported
62 for the treatment of complete tendon rupture (Hirpara et al. 2007; Maquirriain 2011; Merolla et
63 al. 2009; Rawson et al. 2013; Yildirim et al. 2006), but there is a lack of reliable suture methods
64 for the ruptures that involve the muscle belly or MTJ (Faibisoff & Daniel 1981; Kragh et al.
65 2005c; Oliva et al. 2013; Phillips & Hegggers 1988). Complete rupture at the MTJ is particularly
66 difficult, whereas suture of the muscle belly has been previously attempted (Kragh et al. 2005a;
67 Kragh et al. 2005b; Kragh et al. 2005c). The maintenance of the continuity in muscle-tendon unit

68 is important, and strengthening of the adhesion properties is absolutely imperative, as there is a
69 risk of repeated rupture after both surgical and/or non-surgical treatments (Kircher et al. 2010;
70 Young et al. 2014).

71 Furthermore, tearing of the muscle-tendon unit can damage small blood vessels and
72 nerves, generally causing local bleeding, pain, and/or paralysis. Therefore, the early re-
73 establishment of peripheral nerve and blood vessels is important for the muscle repair process, in
74 order to maintain the supply of O₂ and other nutrients, and the removal of CO₂ and other waste
75 products (Ackermann et al. 2002; Ackermann et al. 2003; Nishimori et al. 2012). Additionally, it
76 has been suggested that the repair of tendon ruptures can be stimulated by a single application of
77 several growth factors, including platelet-derived growth factor (PDGF) (Hildebrand et al. 1998),
78 transforming growth factor (TGF)- β (Kashiwagi et al. 2004), insulin-like growth factor (IGF)-1
79 (Kurtz et al. 1999), basic-fibroblast growth factor (bFGF) (Chan et al. 2000), and vascular
80 endothelial growth factor (VEGF) (Zhang et al. 2003). Synchronized supply of these factors is
81 considered beneficial for the reconstruction of the muscle-tendon unit.

82 Therefore, the application of an adhesive able to connect muscles to tendons may be a
83 good treatment strategy for MTJ injury. Several scaffolds have been applied in the tendon healing
84 treatments, and recent tissue-engineering investigations have shown that cell-scaffold constructs
85 can improve the healing of tendon defects, compared with scaffolds alone (Ouyang et al. 2002;
86 Ouyang et al. 2003; Young et al. 1998). Bone marrow-derived mesenchymal stem cells are most
87 frequently applied as adjuvant cells, and their favorable healing effects have been reported
88 (Chong et al. 2007; Ouyang et al. 2004; Ouyang et al. 2002; Ouyang et al. 2003), while the
89 behavior of the transplanted cells, in terms of engraftment and differentiation, is poorly
90 understood. We have determined that skeletal muscle-derived multipotent stem cells (Sk-MSCs)

91 are capable of synchronized reconstitution of muscle-nerve-blood vessel unit and cellular
92 differentiation into skeletal muscle cells, Schwann cells, perineurial/endoneurial cells, pericytes,
93 vascular smooth muscle cells, and endothelial cells (Tamaki et al. 2007a; Tamaki et al. 2005).
94 Recently, we developed a 3D gel-patch tissue reconstitution system using Sk-MSC sheet-pellets,
95 which are able to preferentially reconstitute peripheral nerve and vascular tissues with robust
96 connective tissue networks (Tamaki et al. 2013). Sk-MSC sheet-pellets also expressed various
97 neurotropic/neurotrophic and vasculogenic factor mRNAs before and after transplantation (Soeda
98 et al. 2013; Tamaki et al. 2013). These properties of Sk-MSCs and their sheet-pellets are
99 considered to be beneficial for the reconstitution of muscle-tendon units, including their nerve-
100 blood vessel networks. In this study, we developed a complete rupture model for MTJ in tibialis
101 anterior (TA) muscle of mice, and applied Sk-MSC sheet-pellets as a “bio-bond”-like substance.
102 Functional recovery, which was evaluated by the electrical stimulation-induced muscle
103 contractions via the sciatic nerve, was measured and the behavior of engrafted cells was analyzed
104 immunohistochemically. The putative paracrine capacity of growth factors in the sheet-pellets,
105 relating to skeletal muscle, nerve, and vascular regeneration, was confirmed by RT-PCR and
106 protein array.

107 **MATERIALS AND METHODS**

108 *Animals*

109 Green fluorescent protein transgenic mice (GFP-Tg mice; C57BL/6 TgN[act EGFP]Osb
110 Y01, provided by Dr. M. Okabe, Osaka University, Osaka, Japan) (Okabe et al. 1997) were used
111 as donor mice for the cell transplantation experiments (male, 4-8 week old, n=5), and wild-type
112 mice (C57BL/6N) were used as recipients (male, 8-12 week old, n=13). All experimental

113 procedures were approved by the Tokai University School of Medicine Committee on Animal
114 Care and Use (153015).

115 *Cell Purification and Preparation of Stem Cell Sheet-Pellets*

116 Sk-MSC sheet-pellets (Tamaki et al. 2013) were investigated for their effects on the
117 regeneration of completely ruptured MTJ. Sheet-pellets generally showed gel-like characteristics,
118 and they were able to be lifted using forceps. The thigh and lower leg muscles (tibialis anterior,
119 extensor digitorum longus, soleus, plantaris, gastrocnemius, and quadriceps femoris) of GFP-Tg
120 mice were removed and used in subsequent experiments. Muscle sampling was performed under
121 an overdose of pentobarbital (60 mg/kg, Schering-Plough, combined with butorphanol tartrate 2
122 mg/kg, Meiji Seika, Tokyo, Japan, i.p.). Average total muscle mass removed during the procedure
123 was 512 ± 67 mg/GFP-Tg mouse (mean \pm SE). Muscles were not minced, and were subsequently
124 treated with 0.1% collagenase type IA (Sigma-Aldrich, Tokyo, Japan) in Dulbecco's modified
125 Eagle's medium (DMEM, Wako, Osaka, Japan) containing 7.5% fetal calf serum (FCS, Equitech
126 Bio, TX, USA) with gentle agitation for 30 min at 37°C. Following a short digestion, whole
127 muscles were divided into fiber-bundles, which were washed with culture medium (Iscove's
128 modified Dulbecco's medium; IMDM, Wako, Osaka, Japan) containing 10% FCS, and cultured
129 in IMDM/20% FCS with 100 units/ml penicillin G, 100 μ g/ml streptomycin sulfate (Wako,
130 Osaka, Japan), 10 μ g/ml gentamycin sulfate (Schering-Plough, Osaka, Japan), and 0.1 mM β -
131 mercaptoethanol (Wako, Osaka, Japan) for 3 days. Cultured fiber-bundles associated with
132 expanded cells were treated with trypsin-EDTA (0.05% trypsin, 0.53 mM EDTA; Life
133 Technologies, Tokyo, Japan), in order to dissociate individual cells. Single-cell suspension was
134 filtered through 70-, 40- and 20- μ m nylon filters in order to remove muscle fibers and other

135 debris, and, after washing, isolated cells were re-cultured in IMDM/20% FCS for 2-3 days, until
136 they reached confluence. In total, cells were expanded in culture for 5-6 days, which represents a
137 reduced culture time compared with previous studies (Soeda et al. 2013; Tamaki et al. 2013), thus
138 preserving the myogenic potential of sheet-pellets. After they reached confluence, the cells were
139 gently detached from culture dishes using 2 mM EDTA solution. This step mainly affected Ca²⁺-
140 dependent cell adhesion (e.g., cadherins), while cell-to-cell contact was maintained, sheet-like
141 cell aggregations were collected and centrifuged, and stem cell sheet-pellets were obtained. Total
142 sheet-pellet mass was 120±17 mg/mouse (mean±SE), which means that over 100 mg of sheet-
143 pellets were obtained from about 500 mg of skeletal muscle tissue. Throughout cell isolation, 7.5-
144 10% FCS was added to the collagenase and washing solutions in order to minimize
145 contaminating protease activity and to protect isolated cells as much as possible.

146 *RT-PCR and protein Analysis of the Sheet-pellets*

147 Quality, differentiation potential and relative expressions of cytokines of the cells
148 forming sheet-pellets was confirmed by RT-PCR and antibody array analysis immediately before
149 the transplantation. Cells composed sheet-pellet was prepared for the RT-PCR, and their
150 supernatant was prepared for antibody array analysis. For the RT-PCR analysis, specific primers
151 and the analyzed materials are summarized in **Table 1**. Cells were lysed and total RNA was
152 purified using a QIAGEN RNeasy Micro Kit (Hilden, Germany). First-strand cDNA synthesis
153 was performed with Invitrogen SuperScript III system using dT30-containing primer (see Table
154 1), and specific PCR (35 cycles of 30 s at 94°C, 30 s at 60-65°C and 2 minutes at 72°C) was
155 performed in a 15-µl volume containing Ex-Taq buffer, 0.8 U of ExTaq-HS-polymerase, 0.7 µM
156 specific sense and antisense primers, 0.2 mM dNTPs, and 0.5 µl of cDNA. Relative expression

157 was normalized to the expression of a housekeeping control (HPRT). Details of this analysis were
158 described previously (Tamaki et al. 2013).

159 Concurrently, several cytokines, which are related to the muscular and vascular
160 regeneration were also analyzed by antibody array kit (Proteome Profiler, ARY013, R & D
161 Systems, Minneapolis, MN), as a protein level. Cell culture supernatant of sheet-pellet just before
162 the transplantation was obtained after removal of particulates by centrifugation, and 500- μ l of
163 supernates was prepared for the analysis. Culture medium containing 20% FCS was also prepared
164 for the same analysis in order to check the background effects. The relative expression levels of
165 several cytokines; such as interleukin-6 (IL-6), insulin-like growth factor-1 and 2 (IGF-1 and 2)
166 and their related proteins IGF binding protein-1, 2, 5, and 6 (IGFBP-1, 2, 5 and 6), which are the
167 critical regulator of myogenesis; a regulator/enhancer of macrophage such as chemokine (C-C
168 motif) ligand 2 (MCP-1) and colony stimulating factor 1 (M-CSF); a regulator/activator of wide
169 range of cell types such as fibroblast growth factor-21 (FGF-21) and tissue inhibitor of
170 metalloproteinase 1 (TIMP-1); and vascular endothelial growth factor (VEGF) were determined.

171 *Complete Rupture of MTJ Model and Application of Sheet-Pellets*

172 In order to prepare the experimental complete rupture model, we manually detached
173 muscle fibers from the distal tendons of the right tibialis anterior (TA) muscles of recipient mice
174 (n=13). All surgical preparations were performed under the inhalation anesthesia (Isoflurane;
175 Abbot, Osaka, Japan). A summary of the procedure is shown in **Figure 1**. First, TA muscle was
176 exposed (A, step 1), and muscle fibers were subsequently detached from the distal tendon and
177 peeled off using cotton swabs for one half of the entire TA length (B, step 2), and everted necrotic
178 fiber portions were removed (step 3). The average removed muscle mass was 21.5 ± 1.8 g, and this

179 represented about 40% of total muscle mass. Sheet-pellets were then adhered to the open region
180 of completely ruptured MTJ (**Fig. 1C**, step 4; Sheet-pellet, SP group, n=8), and skin was sutured
181 (C, white arrows). The left side was preserved as a contralateral control. The non-transplanted
182 control group (C group, n=5) underwent the same surgery, and the same amount of cell-free
183 culture medium was administered. The mice were allowed full freedom of movement after
184 surgery.

185 ***Functional Assessment of the Regenerated TA Muscles***

186 After the transplantation, the animals were divided into two groups as short (4-8 weeks)
187 and long (14-18 weeks) term recoveries, and prepared for the functional assessment. The first
188 assessment was begun at 4 weeks using each one mouse in SP and C group, and Tetanic tension
189 outputs of regenerated TA muscles were measured in both left (non-operated control side) and
190 right (operated side) legs. Following assessments were performed every week (1-1.5 week
191 interval) during each group terms using one by one mouse, then, SP and C groups were
192 compared. Measurements were performed *in situ* under inhalation anesthesia (Isoflurane; Abbot,
193 Osaka, Japan), and body (rectal) temperature was maintained at $36\pm 1^{\circ}\text{C}$ with a radiant heat light
194 throughout the measurement. Details of this measurement were as described previously (Tamaki
195 et al. 2005). Briefly, the distal tendon of TA muscle and sciatic nerve (about 10 mm) on both sides
196 were carefully exposed, and tissues were coated with mineral oil to prevent tissue drying and to
197 minimize electrical noise interference. A bipolar silver (Ag/Ag) electrode (inter-electrode
198 distance: 2 mm) was placed under the sciatic nerve. A stainless steel hook was attached to the
199 distal tendon of each TA muscle using a silk ligature. The animal was transferred to a custom-
200 made operating table that allowed stabilization of the head and limbs in a supine position using

201 surgical tape. A stainless steel hook was attached to a force-distance transducer (FD-Pickup, TB-
202 611T; Nihon Kohden, Tokyo, Japan) connected to the carrier amplifier (AP-621G; Nihon
203 Kohden). This enabled the measurements of the muscle contraction force and its distance to be
204 conducted. A bipolar silver electrode (inter-electrode distance: 5 mm/1 mm diameter) was
205 attached to the surface of the reference muscle as well, in order to obtain an evoked electrical
206 myogram, as a confirmation of stable muscle contractions. We have taken care to avoid
207 interference of the reference muscle and nerves with the normal blood supply. Afterward,
208 twitches were elicited by single pulse (1 ms duration, 0.5 Hz) electrical stimulation via the sciatic
209 nerve, at a voltage above the threshold for a maximum response (1.5-4.0 V). Subsequently, peak
210 tetanic tension was determined using stimulation frequencies of 10, 20, 40, 60, 80, 100, 120, and
211 140 Hz of 0.5 s duration at 15 s intervals. The frequency that produced the highest tetanic tension
212 was considered the optimal stimulation for tetanus. All mechanical and electrical measurements
213 were recorded on a Linearcorder (Mark VII, WR3101; Graphtec, Tokyo, Japan) as analog data.
214 The tetanic tension output was considered as the total functional recovery of the operated TA
215 muscle, and recovery ratio was determined based on the contralateral non-operated control side.
216 The same functional measurements were also performed at 10 weeks post-transplantation, in
217 order to assess the progress of recovery.

218 ***Macroscopic Observation and Immunostaining***

219 Following the functional measurements above, recipient mice (including the animals
220 used for morphological analysis only, 5-10 weeks after transplantation, n=5) were given an
221 overdose of pentobarbital (60 mg/kg, combined with butorphanol tartrate 2 mg/kg, i.p.), and the
222 engraftment of donor-derived GFP⁺ cells into the damaged portion of TA muscle was confirmed
223 by fluorescence stereomicroscopy (SZX12; Olympus, Tokyo, Japan, **Figure 4**). Recipient mice
224 were perfused with warm 0.01 M phosphate-buffered saline (PBS, Wako, Osaka, Japan) through
225 the left ventricle, followed by fixation with 4% paraformaldehyde /0.1 M phosphate buffer (4%
226 PFA/PB, Wako, Osaka, Japan). Muscles were removed and fixed overnight in 4% PFA/PB,
227 washed with graded sucrose (0-25%, Wako, Osaka, Japan)/0.01 M PBS series, and quick frozen
228 with isopentane (Wako, Osaka, Japan) pre-cooled by liquid nitrogen, followed by storage at
229 -80°C. Subsequently, 7 µm cross-sections were obtained. Skeletal muscle fibers were stained
230 with anti-skeletal muscle actin (αSkMA; dilution, 1:200; incubation, room temperature for 2 h;
231 Abcam, Cambridge, UK). Nerve fiber localization (axons) was detected by rabbit polyclonal anti-
232 Neurofilament 200 (N-200, dilution, 1:1000; incubation, room temperature for 1 h; Sigma, St.
233 Louis, MO, USA). Schwann cells were detected using anti-p75 (rabbit polyclonal, 1:400, 4°C
234 overnight; CST, Boston, MA, USA). Blood vessels were detected with rat anti-mouse CD31
235 (1:500, 4°C overnight; BD Pharmingen, San Diego, CA, USA) monoclonal antibody, which is a
236 known vascular endothelial cell marker, and mouse monoclonal α-smooth muscle actin (αSMA,
237 Cy3-conjugated; 1:1500; room temperature for 1 h; Sigma, St. Louis, MO, USA). Dystrophin
238 formation in the skeletal muscle fibers was detected using goat anti-dystrophin polyclonal
239 antibody (1:50, 4°C, overnight; Santa Cruz Biotechnology, Dallas, TX, USA). Neuromuscular
240 junctions were detected by α-bungarotoxin (Alexa Fluor 594 conjugated, 1:100, room
241 temperature, 1 h; Molecular Probes, Eugene, OR, USA). Reactions were visualized using Alexa

242 Fluor-594-conjugated goat anti-rabbit and anti-rat antibodies (1:500, room temperature, 2 h;
243 Molecular Probes, Eugene, OR, USA). Nuclei were counter-stained with DAPI (4,6-diamino-2-
244 phenylindole).

245 *Statistical Analysis*

246 Differences between two groups (short and long term recovery group) were tested using
247 Student's t test, and the significance level was set at $p < 0.05$. Values are expressed as mean \pm SE.

248 RESULTS

249 *Quality and Therapeutic Potential of Sk-MSC Sheet-pellets*

250 Quality, differentiation, and putative therapeutic potential of the sheet-pellet were first
251 confirmed by RT-PCR and protein array analysis (**Figure 2**). The expression of specific
252 myogenic, neurotrophic, and vasculogenic factor mRNAs in the sheet-pellets immediately before
253 the transplantation is shown in **Figure 2A**. The Sk-MSC sheet-pellets showed expressions of
254 various myogenic factors (MyoD, Myf5, Pax7, Myogenin, c-met, Mcad, MyH, Desmin, and IGF-
255 1), neurotrophic factors (NGF, BDNF, GDNF, CNTF, LIF, Ninjurin, Galectin, Nestin, and Sox10)
256 and vascular growth factors (VEGF, HGF, PDGF, TGF- β , EGF, and FGFb), except Pax3. These
257 results agree with a previous report (Tamaki et al. 2013), which showed good quality of this
258 method of sheet-pellet preparation.

259 In addition, relative increase in the expressions of proteins (cytokines) was also detected
260 in the same sheet-pellet culture supernatant (**Figure 2B**). An increase of myokine (Munoz-
261 Canoves et al. 2013; Pedersen 2012), which is a critical regulator of muscle regeneration, such as

262 IL-6 and IGF-1 and 2 associate with their relating IGFBP-2, 3, 5 and 6, the chemokine, which is
263 an up-regulator of monocyte/macrophage (MCP-1 and M-CSF) in the tissue regeneration
264 (Pantsulaia et al. 2005; Shiba et al. 2007), and a regulator/activator of a wide range of cell types
265 (FGF-21 and TIMP-1) (Mas et al. 2007; Wan 2013) was detected, showing a paracrine capacity
266 of the sheet-pellet.

267 *Functional Recovery*

268 The results of functional assessment are summarized in **Table 2**. The SP short term
269 recovery group showed average 64% recovery of muscle mass, and 36% recovery of tetanic
270 tension output relative to the contralateral side. Then, the SP long term recovery group showed
271 increased recovery of average muscle mass (77%) and tetanic tension output (49%). The age-
272 dependent increase in muscle mass was also observed between short (4-8 weeks) and long (14-18
273 weeks) term recovery group (45.2 ± 5.8 to 50.4 ± 0.5 mg). Importantly, the control group did not
274 recover the continuity of the muscle-tendon unit, and the remaining muscles showed atrophy with
275 coalescence into the tibial bone in the short term group (see next **Fig. 4I and J**), thus showing
276 that this model is irreversible spontaneously. Therefore, we were unable to continue measuring
277 muscle mass and tension output in the Control group subsequently.

278 Differences of operated-muscle mass and tetanic tension recoveries between the short
279 and long term groups, and these composed individual plots at each measurement point are also
280 shown in **Figure 3**. Average of muscle mass and tension output were both higher in the long term
281 group (**Fig. 3A, B**), showing that a development of recoveries continued over 14 weeks after
282 operation. On the individual plot, a term depends manner of recoveries were clearly observed in
283 the long term group as a linear relationship, but not in the short term group (**Fig. 3C and D**). This

284 may be representing the effect of standard body activities of mice in the cages, because general
285 activities (go around, hanging and downside walking of cage lid) were clearly higher in the long
286 term recovery group than that in the short term group by our animal care observations (data not
287 shown).

288 *Macroscopic Examination*

289 Typical fluorescence macroscopic features at 4-10 weeks after the engraftment of
290 transplanted GFP⁺ sheet-pellets are shown in **Figure 4**. *In situ* observation revealed that a large
291 volume of GFP⁺ tissues was engrafted in the damaged TA muscle portion after transplantation,
292 and these tissues showed 5 different patterns. Pattern 1 was the most common one (5/13
293 samples), showing broad and thick engraftment through the tendon to the mid portion of the
294 muscle (**Figs. 4A-C**). GFP⁺ engrafted tissue was observed in blood vessel networks (arrows in
295 **Fig. 4B**), and the continuity was clearly maintained (**Fig. 4C**). This pattern was mainly composed
296 of connective tissue with few muscle fibers. Pattern 2 was rarely observed (1/13 samples), and it
297 mostly comprised of the muscle fibers (**Fig. 4D**) that extended from the mid portion of MTJ to
298 the upper portion, and with few connective tissues. Pattern 3 (1/13 samples) in contrast, mainly
299 comprised of the connective tissue at the distal portion of MTJ, with few muscle fibers (**Fig. 4E**).
300 Patterns 4 (3/13 samples) and 5 (3/13 samples) were mixed types, showing both muscle fibers
301 and connective tissues (**Figs. 4F-H**), but GFP was relatively sparse, and the amount of connective
302 tissues was small in Pattern 4 (**Fig. 4F**), while Pattern 5 showed even distribution of both tissues
303 (**Fig. 4G**). Active blood vessels in and around GFP⁺ tissues were equally observed in all Patterns
304 (arrows in **Figs. 4B, and 4D-4H**).

305 Severe atrophy of TA muscle was generally observed in the C group (**Figs. 4I and 4J**), and this

306 pattern was observed in 5/5 control mice. On the lateral side of the tibia (black arrows in **Figs. 4I**
307 and **4J**), a portion of the TA muscle was clearly hollowed (white arrows in **Fig. 4I**), and there
308 were no muscle fibers present. Apparent adipose tissue formation (red arrows in **Fig. 4J**) was also
309 observed, suggesting discontinuity of the TA muscle-tendon unit (**Fig. 4J**).

310 *Immunohistochemical Analysis of the Engrafted Cells*

311 At 4-10 weeks following the surgery, the behavior of engrafted GFP⁺ cells was analyzed
312 in cross-sections. **Figure 5** shows the result of Pattern 1. Thick tissues composed of GFP⁺ cells
313 closely adhered to skeletal muscle fibers (**Fig. 5A**). GFP⁺ cells surrounded the tendon, and van
314 Gieson elastic fiber staining showed connective tissue networks (**Fig. 5B**). This suggests that the
315 engrafted GFP⁺ tissue formed connective tissue networks, which connected both the tendon and
316 the muscle fibers, displaying a “bio-bond” role. Additionally, GFP⁺ cells were observed in the
317 tendon (yellow arrows in **Fig. 5C**), and showed differentiation into vascular endothelial cells
318 (CD31 + GFP, white arrows in **5C**). A similar trend was also observed on the muscle fiber side,
319 and the migration of GFP⁺ cells could be seen between muscle fibers (**Fig. 5D**, below the dotted
320 line). A close relationship (not double staining) of N200⁺ nerve axons and GFP⁺ cells, was
321 observed on both the muscle side (below the dotted line) and the connective tissue side (**Fig. 5D**,
322 upper-side of dotted line). GFP⁺ cells in the connective tissue were positive for p75 (**Fig. 5E**,
323 right side of dotted line) and therefore, they were considered Schwann cells. These results
324 support a close relationship between GFP⁺ cells and nerve axons, which is detectable in **Figure**
325 **5D**. The relationship among engrafted GFP⁺ connective tissue, tendon, and muscle fibers is more
326 apparent in **Figure 4F**. GFP⁺ connective tissue bridging tendon (T) and muscle fibers (right side
327 of the panel) expressed dystrophin (red), which suggests a strong relationship between connective

328 tissue and muscle fibers through dystrophin complexes.

329 Similarly, longitudinal profiles obtained from pattern 5 are shown in **Figure 6**. Engrafted
330 GFP⁺ cell-derived connective tissues closely adhered to the muscle fibers (**Fig. 6A**), and GFP⁺
331 muscle fibers were also observed (**Fig. 6B**). Differentiation of GFP⁺ cells into vascular smooth
332 muscle cells was seen in the connective tissue network (**Fig. 6C**, arrows, double staining with
333 GFP+SMA), contributing to a relatively large blood vessel formation. The involvement in the
334 peripheral nerve reconstitution was indicated by a close relationship between GFP⁺ cells and
335 axons (**Fig. 6D**, arrows, close distributions of GFP⁺ cells and N200⁺ axons). This relationship was
336 supported by the differentiation of GFP⁺ cells into Schwann cells positive for p75 (**Fig. 6E**,
337 arrows, double staining of GFP+p75). Similarly, a close relationship of GFP⁺ cells and muscle
338 fibers, nerve axons, and the neuromuscular junctions was evident (**Fig. 6F**, in the dotted line
339 circle as α -bungarotoxin⁺), confirming that GFP⁺ cells contributed to peripheral nerve extensions,
340 reaching to the end of a motor nerve. These results indicate that the transplanted GFP⁺ Sk-MSC
341 sheet-pellets mainly form connective tissue networks together with a certain amount of muscle
342 fibers, and that they physically bind the tendon and muscle fibers, contributing to the peripheral
343 nerve-blood vessel formation.

344 **DISCUSSION**

345 Injuries involving the muscle belly or MTJ are challenging for surgeons because the
346 muscle tissue shows poor suture-holding capacity, and the reliable suture methods have not been
347 established yet (Faibisoff & Daniel 1981; Kragh et al. 2005c; Oliva et al. 2013; Phillips &
348 Heggers 1988). However, reconstruction and/or re-establishment of continuity in the muscle-

349 tendon unit is vital for the functional repair, because of the primary role of muscle force
350 generation and transmission. We have investigated the reconstruction of completely ruptured TA
351 muscle at the MTJ, using Sk-MSC sheet-pellets as "bio-bonds." The results indicate that Sk-MSC
352 sheet-pellet transplantation achieved favorable results in the reconstruction and/or reconnection
353 of the ruptured muscles and tendons. Engrafted Sk-MSCs primarily formed connective tissues,
354 including neurovascular networks, and bridged both the tendon and muscle fibers, with
355 differentiation into skeletal muscle fibers, Schwann cells, vascular smooth muscles, and
356 endothelial cells. The differentiation capacity of these cells was previously predicted, since the
357 present sheet-pellet was mainly composed of the mixed population of multipotent Sk-34
358 (CD34⁺/45⁻) (Tamaki et al. 2002; Tamaki et al. 2005) and Sk-DN (CD34⁺/45⁻) (Tamaki et al. 2003;
359 Tamaki et al. 2007a; Tamaki et al. 2007b) cells, and their putative potential for the therapy was
360 confirmed by RT-PCR and protein array analysis immediately before the transplantation (**Fig. 2A**
361 **and B**). Furthermore, the migration of engrafted GFP⁺ fibroblast-like cells was observed around
362 the tendon and the interstitium of muscle fibers, mechanically bridging the tendon-muscle gap.
363 This reconnecting behavior is considered the "bio-bond" activity. Establishment of a muscle fiber
364 holding capacity in donor-derived connective tissue was further suggested by the expression of
365 dystrophin in MTJ fibers (**Fig. 5F**), because of the role of dystrophin-dystroglycan (α , β) complex
366 in the collagen network (Monti et al. 1999; Welser et al. 2009). In our previous studies, we
367 prepared the sheet-pellets as the accelerators of the neurovascular reconstitution with diminished
368 myogenic potential (Soeda et al. 2013; Tamaki et al. 2013). Here, we used a shorter term
369 expansion culture (in particular, the term of first fiber culture), and this shorter culture period
370 helped preserve the myogenic potential of the sheet-pellets, resulting in new myofiber formation.
371 This was confirmed by the comparison of the RT-PCR data obtained in the previous studies

372 (Soeda et al. 2013; Tamaki et al. 2013) and the results obtained in this one (**Fig. 2**). The relatively
373 preserved myofiber formation capacity may have also contributed to the enhanced connection of
374 the muscle-tendon unit.

375 The investigated sheet-pellets contributed to functional regeneration of disrupted TA
376 muscles by 36% in the short term recovery group, and this increased 49% in the long term
377 recovery group. Concerning to the relationship between the engrafted patterns (**Fig. 4**) and
378 functions, relatively higher contractions were dominantly observed in the Pattern 4 and 5 (**Fig. 4F**
379 and **G**), which showed mixed types of GFP engraftment of both muscle fibers and connective
380 tissues. The tension recoveries were further supported by the immunohistochemical staining
381 results, showing that GFP⁺ cells contributed to motor nerve extensions, close to the
382 neuromuscular junctions (**Fig. 6F**, from Pattern 5). We did not perform the tensile strength test of
383 the regenerated muscles, but no muscle ruptures were observed during repetitive maximum
384 tetanic tension measurements. In addition, the absolute value of the tension output of operated-
385 muscles (around 38 g) was superior to the mean body weight (around 34 g) in the long term
386 group. Therefore, we believe that the tensile strength of operated-muscle may have been
387 sufficient to support standard body activities, and it could be enhanced, as one type of
388 rehabilitation, which resulted in an increased tension recovery in the long term group (**Table 2**
389 and **Fig. 3A, B**). The notion of this rehabilitation (increased body activity) depends increase in
390 the tension recovery was further suggested by the term dependent linear relationship, as was
391 observed particularly in the individual plots of the long term group (**Fig. 3D**). Because we
392 observed enhanced general cage activities of the mice in the long term group compared to the
393 short term group, and the same trend was also detected clearly in the muscle mass recovery (**Fig.**
394 **3C**). Thus, we believe that this linear relationship may be due to an increased general activity of

395 mice day by day following the improvement in the general symptoms, such as reduced pain and
396 uncomfortable feeling. In this regard, it was suggested that these symptoms were more prominent
397 in the short term group, and may induce lower activities. However, this lower activity might be a
398 benefit for tissue recovery by contraries. By these reasons, it was also suggested that an earlier
399 start of positive rehabilitation, probably around 8 weeks after operation, may have more rapid and
400 enhanced recovery of this therapy was expected.

401 As a consequence, the non-transplanted control group did not achieve reconnection of
402 muscle-tendon units (**Fig. 4** and **Table 2**), showing that the MTJ rupture model we used is an
403 irreversible model. It has been reported that the early reconnection induced mechanical
404 stimulation is effective for the repair and quality maintenance of the tendon, because the lack of
405 this stimulation produced detrimental effects (Lin et al. 2004; Matsumoto et al. 2003). Therefore,
406 we concluded that the absence of mechanical-tension in the control group, after the complete
407 removal of the MTJ, may have caused a massive muscle atrophy associated with the fatty tissue
408 replacement (**Fig. 4**). It is also a fact that the present sheet-pellets transplantation prevented this
409 detrimental effects.

410 Additionally, it has been suggested that early peripheral nerve regeneration and the
411 provision of neuropeptides are important for the healing of normal connective tissue and tendon
412 (Ackermann et al. 2002; Ackermann et al. 2003). Neovascularization plays a critical role in the
413 healing process of the ligament (Nishimori et al. 2012). The repair of angiokinesis (vasodilation-
414 constriction) through the neurovascular regeneration is also important for tissue regeneration
415 (Ackermann et al. 2002). Our treatment meets all these conditions. Previous studies demonstrated
416 that Sk-MSCs transplantation facilitates/accelerates nerve-vascular formation (Tamaki et al.
417 2014; Tamaki et al. 2007a; Tamaki et al. 2013; Tamaki et al. 2005). The expressions of various

418 nerve-blood vessel-related growth and trophic factors before and after transplantation was also
419 observed in the case of nerve-gap regeneration (Tamaki et al. 2014). In our study, prolonged
420 expression of these genes, shown in **Figure 2**, was expected and observed following the
421 transplantation, and it may be beneficial for the healing of muscle-tendon units.

422 We recently established a practical/therapeutic method of isolation of human skeletal muscle-
423 derived stem cells (Tamaki et al. 2015). Using this method, we found that human cells can be
424 divided into 2 stem/progenitor cell fractions; 1) the cells showing preferential differentiation into
425 the skeletal myogenic lineage ($CD45^-/CD34^-/29^+ = Sk-DN/29^+$), and 2) cells showing multiple
426 differentiation into nerve-blood vessel cell lineages ($CD45^-/34^+ = Sk-34$). The combined
427 differentiation/reconstitution capacities of these cells after *in vivo* transplantation were
428 comparable to the mouse Sk-MSCs (Tamaki et al. 2015). Therefore, the cell fractions could be
429 selected and adjusted for the treatment of muscle fibers, nerve-blood vessels associated with
430 connective tissues, or both. Additionally, these stem/progenitor cells can be obtained from various
431 muscle regions, including the legs and abdominals (Tamaki et al. 2015). The removal of a small
432 sample (around 3 g) from the lower abdominal wall muscle carries low risk to the loss of motor
433 function.

434 CONCLUSIONS

435 In the present study, we successfully demonstrated that Sk-MSC sheet-pellet
436 transplantation can bridge complete rupture of MTJ, and form connective tissue networks
437 associated with cellular differentiation into skeletal muscle fibers, Schwann cells, vascular
438 smooth muscle, and endothelial cells. These connective tissues migrated around the tendon and
439 muscle fiber interstitium and connected both tissues, playing a role of a "bio-bond." Paracrine

440 effects of nerve and vascular growth factors, as well as trophic factors, produced by Sk-MSCs
441 may also be beneficial for the reparation of the tissue. Together with the recent establishment of
442 human skeletal muscle-derived cells, Sk-MSCs may be an optimal autologous cell source, used as
443 an adjuvant, which would lead to a promising therapy for muscle-tendon injuries. Furthermore,
444 the combined therapies, such as an appropriate suture with sheet-pellet, or suture together with
445 sheet-pellet and scaffold use, may also represent favorable therapies for the MTJ rupture repair,
446 particularly because of the higher tensile strength required in humans.

447 REFERENCES

- 448 Ackermann PW, Ahmed M, and Kreicbergs A. 2002. Early nerve regeneration after achilles
449 tendon rupture--a prerequisite for healing? A study in the rat. *J Orthop Res* 20:849-856.
450 10.1016/S0736-0266(01)00159-0
- 451 Ackermann PW, Li J, Lundeborg T, and Kreicbergs A. 2003. Neuronal plasticity in relation to
452 nociception and healing of rat achilles tendon. *J Orthop Res* 21:432-441. 10.1016/S0736-
453 0266(02)00207-3
- 454 Chan BP, Fu S, Qin L, Lee K, Rolf CG, and Chan K. 2000. Effects of basic fibroblast growth
455 factor (bFGF) on early stages of tendon healing: a rat patellar tendon model. *Acta Orthop*
456 *Scand* 71:513-518. 10.1080/000164700317381234
- 457 Chan O, Del Buono A, Best TM, and Maffulli N. 2012. Acute muscle strain injuries: a proposed
458 new classification system. *Knee Surg Sports Traumatol Arthrosc* 20:2356-2362.
459 10.1007/s00167-012-2118-z
- 460 Chong AK, Ang AD, Goh JC, Hui JH, Lim AY, Lee EH, and Lim BH. 2007. Bone marrow-
461 derived mesenchymal stem cells influence early tendon-healing in a rabbit achilles tendon
462 model. *J Bone Joint Surg Am* 89:74-81. 10.2106/JBJS.E.01396
- 463 ElMaraghy AW, and Devereaux MW. 2012. A systematic review and comprehensive
464 classification of pectoralis major tears. *J Shoulder Elbow Surg* 21:412-422.
465 10.1016/j.jse.2011.04.035
- 466 Faibisoff B, and Daniel RK. 1981. Management of severe forearm injuries. *Surg Clin North Am*
467 61:287-301.
- 468 Hildebrand KA, Woo SL, Smith DW, Allen CR, Deie M, Taylor BJ, and Schmidt CC. 1998. The

- 469 effects of platelet-derived growth factor-BB on healing of the rabbit medial collateral
470 ligament. An in vivo study. *Am J Sports Med* 26:549-554.
- 471 Hirpara KM, Sullivan PJ, Raheem O, and O'Sullivan ME. 2007. A biomechanical analysis of
472 multistrand repairs with the Silfverskiold peripheral cross-stitch. *J Bone Joint Surg Br*
473 89:1396-1401. 10.1302/0301-620X.89B10.19360
- 474 Kashiwagi K, Mochizuki Y, Yasunaga Y, Ishida O, Deie M, and Ochi M. 2004. Effects of
475 transforming growth factor-beta 1 on the early stages of healing of the Achilles tendon in
476 a rat model. *Scand J Plast Reconstr Surg Hand Surg* 38:193-197.
477 10.1080/02844310410029110
- 478 Kircher J, Ziskoven C, Patzer T, Zaps D, Bittersohl B, and Krauspe R. 2010. Surgical and
479 nonsurgical treatment of total rupture of the pectoralis major muscle in athletes: update
480 and critical appraisal. *Open Access J Sports Med* 1:201-205. 10.2147/OAJSM.S9066
- 481 Kragh JF, Jr., Svoboda SJ, Wenke JC, Brooks DE, Bice TG, and Walters TJ. 2005a. The role of
482 epimysium in suturing skeletal muscle lacerations. *J Am Coll Surg* 200:38-44.
483 10.1016/j.jamcollsurg.2004.09.009
- 484 Kragh JF, Jr., Svoboda SJ, Wenke JC, Ward JA, and Walters TJ. 2005b. Epimysium and
485 perimysium in suturing in skeletal muscle lacerations. *J Trauma* 59:209-212.
- 486 Kragh JF, Jr., Svoboda SJ, Wenke JC, Ward JA, and Walters TJ. 2005c. Suturing of lacerations of
487 skeletal muscle. *J Bone Joint Surg Br* 87:1303-1305. 10.1302/0301-620X.87B9.15728
- 488 Kurtz CA, Loebig TG, Anderson DD, DeMeo PJ, and Campbell PG. 1999. Insulin-like growth
489 factor I accelerates functional recovery from Achilles tendon injury in a rat model. *Am J*
490 *Sports Med* 27:363-369.
- 491 Lin TW, Cardenas L, and Soslowsky LJ. 2004. Biomechanics of tendon injury and repair. *J*
492 *Biomech* 37:865-877. 10.1016/j.jbiomech.2003.11.005
- 493 Maquirriain J. 2011. Achilles tendon rupture: avoiding tendon lengthening during surgical repair
494 and rehabilitation. *Yale J Biol Med* 84:289-300.
- 495 Mas VR, Maluf DG, Archer KJ, Yanek KC, and Fisher RA. 2007. Angiogenesis soluble factors as
496 hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic
497 patients awaiting liver transplantation. *Transplantation* 84:1262-1271.
498 10.1097/01.tp.0000287596.91520.1a
- 499 Matsumoto F, Trudel G, Uthoff HK, and Backman DS. 2003. Mechanical effects of
500 immobilization on the Achilles' tendon. *Arch Phys Med Rehabil* 84:662-667.
- 501 Merolla G, Campi F, Paladini P, and Porcellini G. 2009. Surgical approach to acute pectoralis
502 major tendon rupture. *G Chir* 30:53-57.
- 503 Monti RJ, Roy RR, Hodgson JA, and Edgerton VR. 1999. Transmission of forces within
504 mammalian skeletal muscles. *J Biomech* 32:371-380.

- 505 Munoz-Canoves P, Scheele C, Pedersen BK, and Serrano AL. 2013. Interleukin-6 myokine
506 signaling in skeletal muscle: a double-edged sword? *FEBS J* 280:4131-4148.
507 10.1111/febs.12338
- 508 Nishimori M, Matsumoto T, Ota S, Kopf S, Mifune Y, Harner C, Ochi M, Fu FH, and Huard J.
509 2012. Role of angiogenesis after muscle derived stem cell transplantation in injured
510 medial collateral ligament. *J Orthop Res* 30:627-633. 10.1002/jor.21551
- 511 Okabe M, Ikawa M, Kominami K, Nakanishi T, and Nishimune Y. 1997. 'Green mice' as a source
512 of ubiquitous green cells. *FEBS Lett* 407:313-319. S0014-5793(97)00313-X [pii]
- 513 Oliva F, Via AG, Kiritsi O, Foti C, and Maffulli N. 2013. Surgical repair of muscle laceration:
514 biomechanical properties at 6 years follow-up. *Muscles Ligaments Tendons J* 3:313-317.
- 515 Ouyang HW, Goh JC, and Lee EH. 2004. Use of bone marrow stromal cells for tendon graft-to-
516 bone healing: histological and immunohistochemical studies in a rabbit model. *Am J*
517 *Sports Med* 32:321-327.
- 518 Ouyang HW, Goh JC, Mo XM, Teoh SH, and Lee EH. 2002. The efficacy of bone marrow
519 stromal cell-seeded knitted PLGA fiber scaffold for Achilles tendon repair. *Ann N Y Acad*
520 *Sci* 961:126-129.
- 521 Ouyang HW, Goh JC, Thambyah A, Teoh SH, and Lee EH. 2003. Knitted poly-lactide-co-
522 glycolide scaffold loaded with bone marrow stromal cells in repair and regeneration of
523 rabbit Achilles tendon. *Tissue Eng* 9:431-439. 10.1089/107632703322066615
- 524 Pantsulaia I, Trofimov S, Kobylansky E, and Livshits G. 2005. Contribution of the familial and
525 genetic factors on monocyte chemoattractant protein-1 variation in healthy human
526 pedigrees. *Cytokine* 32:117-123. 10.1016/j.cyto.2005.08.006
- 527 Pedersen BK. 2012. Muscular interleukin-6 and its role as an energy sensor. *Med Sci Sports*
528 *Exerc* 44:392-396. 10.1249/MSS.0b013e31822f94ac
- 529 Phillips LG, and Heggors JP. 1988. Layered closure of lacerations. *Postgrad Med* 83:142-148.
- 530 Rawson S, Cartmell S, and Wong J. 2013. Suture techniques for tendon repair; a comparative
531 review. *Muscles Ligaments Tendons J* 3:220-228.
- 532 Shiba Y, Takahashi M, Yoshioka T, Yajima N, Morimoto H, Izawa A, Ise H, Hatake K, Motoyoshi
533 K, and Ikeda U. 2007. M-CSF accelerates neointimal formation in the early phase after
534 vascular injury in mice: the critical role of the SDF-1-CXCR4 system. *Arterioscler*
535 *Thromb Vasc Biol* 27:283-289. 10.1161/01.ATV.0000250606.70669.14
- 536 Soeda S, Tamaki T, Hashimoto H, Saito K, Sakai A, Nakajima N, Nakazato K, Masuda M, and
537 Terachi T. 2013. Functional Nerve-Vascular Reconstitution of the Bladder-Wall;
538 Application of Patch Transplantation of Skeletal Muscle-Derived Multipotent Stem Cell
539 Sheet-Pellets. *J Stem Cell Res Ther* 3:142.
- 540 Tamaki T, Akatsuka A, Ando K, Nakamura Y, Matsuzawa H, Hotta T, Roy RR, and Edgerton VR.

- 541 2002. Identification of myogenic-endothelial progenitor cells in the interstitial spaces of
542 skeletal muscle. *J Cell Biol* 157:571-577.
- 543 Tamaki T, Akatsuka A, Okada Y, Matsuzaki Y, Okano H, and Kimura M. 2003. Growth and
544 differentiation potential of main- and side-population cells derived from murine skeletal
545 muscle. *Exp Cell Res* 291:83-90.
- 546 Tamaki T, Hirata M, Soeda S, Nakajima N, Saito K, Nakazato K, Okada Y, Hashimoto H,
547 Uchiyama Y, and Mochida J. 2014. Preferential and comprehensive reconstitution of
548 severely damaged sciatic nerve using murine skeletal muscle-derived multipotent stem
549 cells. *PLoS One* 9:e91257. 10.1371/journal.pone.0091257
550 PONE-D-13-38421 [pii]
- 551 Tamaki T, Okada Y, Uchiyama Y, Tono K, Masuda M, Wada M, Hoshi A, and Akatsuka A. 2007a.
552 Synchronized reconstitution of muscle fibers, peripheral nerves and blood vessels by
553 murine skeletal muscle-derived CD34(-)/45 (-) cells. *Histochem Cell Biol* 128:349-360.
554 10.1007/s00418-007-0331-5
- 555 Tamaki T, Okada Y, Uchiyama Y, Tono K, Masuda M, Wada M, Hoshi A, Ishikawa T, and
556 Akatsuka A. 2007b. Clonal multipotency of skeletal muscle-derived stem cells between
557 mesodermal and ectodermal lineage. *Stem Cells* 25:2283-2290. 2006-0746 [pii]
558 10.1634/stemcells.2006-0746
- 559 Tamaki T, Soeda S, Hashimoto H, Saito K, Sakai A, Nakajima N, Masuda M, Fukunishi N,
560 Uchiyama Y, Terachi T, and Mochida J. 2013. 3D reconstitution of nerve-blood vessel
561 networks using skeletal muscle-derived multipotent stem cell sheet pellets. *Regen Med*
562 8:437-451. 10.2217/rme.13.30
- 563 Tamaki T, Uchiyama Y, Hirata M, Hashimoto H, Nakajima N, Saito K, Terachi T, and Mochida J.
564 2015. Therapeutic isolation and expansion of human skeletal muscle-derived stem cells
565 for the use of muscle-nerve-blood vessel reconstitution. *Front Physiol* 6:165.
566 10.3389/fphys.2015.00165
- 567 Tamaki T, Uchiyama Y, Okada Y, Ishikawa T, Sato M, Akatsuka A, and Asahara T. 2005.
568 Functional recovery of damaged skeletal muscle through synchronized vasculogenesis,
569 myogenesis, and neurogenesis by muscle-derived stem cells. *Circulation* 112:2857-2866.
- 570 Wan Y. 2013. Bone marrow mesenchymal stem cells: fat on and blast off by FGF21. *Int J*
571 *Biochem Cell Biol* 45:546-549. 10.1016/j.biocel.2012.12.014
- 572 Welser JV, Rooney JE, Cohen NC, Gурpur PB, Singer CA, Evans RA, Haines BA, and Burkin
573 DJ. 2009. Myotendinous junction defects and reduced force transmission in mice that lack
574 alpha7 integrin and utrophin. *Am J Pathol* 175:1545-1554. 10.2353/ajpath.2009.090052
- 575 Yildirim Y, Saygi B, Kara H, Cabukoglu C, and Esemeli T. 2006. [Tendon holding capacities of
576 the suture materials used in repairing Achilles tendon rupture]. *Acta Orthop Traumatol*

- 577 *Turc* 40:164-168.
- 578 Young RG, Butler DL, Weber W, Caplan AI, Gordon SL, and Fink DJ. 1998. Use of
579 mesenchymal stem cells in a collagen matrix for Achilles tendon repair. *J Orthop Res*
580 16:406-413. 10.1002/jor.1100160403
- 581 Young SW, Patel A, Zhu M, van Dijck S, McNair P, Bevan WP, and Tomlinson M. 2014. Weight-
582 Bearing in the Nonoperative Treatment of Acute Achilles Tendon Ruptures: A
583 Randomized Controlled Trial. *J Bone Joint Surg Am* 96:1073-1079.
584 10.2106/JBJS.M.00248
- 585 Zhang F, Oswald T, Lin S, Cai Z, Lei M, Jones M, Angel MF, and Lineaweaver WC. 2003.
586 Vascular endothelial growth factor (VEGF) expression and the effect of exogenous VEGF
587 on survival of a random flap in the rat. *Br J Plast Surg* 56:653-659.

588 **FIGURE LEGENDS**

589 **Figure 1.** Macroscopic and schematic images of procedures used in MTJ complete rupture
590 model preparation and sheet-pellet transplantation. Photographs of a left-TA muscle were taken.
591 A = Step 1; B = Step 2; and C = Step 4. Dotted circle in B shows peeling of fibers. White arrows
592 in C show partially sutured skin. Bars = 1 mm.

593 **Figure 2.** RT-PCR analysis of Sk-MSC sheet-pellet and its expressions of cytokines immediately
594 prior to transplantation. (A) Expressions of myogenic, neurotrophic, and vasculogenic factor
595 mRNAs was observed, confirming the quality of the sheet-pellet preparation. bp = base pair. (B)
596 Several cytokines related to the muscle and vascular regeneration was also detected in the culture
597 supernatant of the sheet-pellet, confirming the putative capacity of paracrine.

598 **Figure 3.** Differences of operated TA muscle mass and tetanic tension output between the short
599 (4-8 weeks) and long (14-18 weeks) term groups, and these composed individual plots at each

600 measurement point. Average of operated muscle mass (A) and tetanic tension output (B) were
601 higher in the long term group (but not significant). (C and D) Linear relationships between term
602 and recovery are detected on the individual plots of the long term group, but not in the short term
603 group both in the muscle mass (C) and tetanic tension output (D).

604 **Figure 4.** Macroscopic observation of surgically treated TA muscles at 5-10 weeks after
605 transplantation *in situ* and *in vitro* (after removal). Photographs were taken by synchronizing light
606 conditions as the fluorescence + normal. (A-G) Typical features of sheet-pellet (GFP⁺)
607 transplanted muscles. A-C = Pattern 1, D = Pattern 2, E = Pattern 3, F = Pattern 4, and G-H =
608 Pattern 5. Arrows in B, D, E, F, G, and H show blood vessels. (I and J) Typical features of media
609 transplanted control muscles. White arrows in panel I show the dent in the TA position. Red
610 arrows in panel J show fat tissue. Black arrows in I and J indicate tibial bone. Bars = 1 mm.

611 **Figure 5.** Immunohistochemical detection of engrafted Sk-MSCs in cross-section (operated
612 muscle from Pattern 1, 7 weeks after operation). (A and B) Relationship among the GFP⁺ cell-
613 derived connective tissue, recipient tendon, and muscle fibers. Skeletal muscle fibers were
614 stained with Sk-actin (skeletal muscle actin, A), and tendon and connective tissues were stained
615 with Elastica Van Gieson (B). (C) Endothelial cell staining with CD31. (D) Axon staining with
616 Neurofilament 200 (N200). (E) Schwann cell staining with p75. (F) Dystrophin staining for
617 skeletal muscle fibers in the MTJ. Muscle fibers expressing dystrophin (red reactions). T =
618 tendon. Dotted lines in D and E show the border between connective tissue and muscle fibers.
619 Blue staining = DAPI. Bars in A and B = 200 μm, C-E = 100 μm.

620 **Figure 6.** Immunohistochemical detection of engrafted Sk-MSCs in longitudinal sections
 621 (operated muscle from Pattern 5, 8 weeks after operation). (A) Close relationship between donor-
 622 derived GFP⁺ connective tissue and muscle fibers was also apparent in the longitudinal images.
 623 (B) GFP⁺ muscle fibers were observed. (C) Vascular smooth muscle staining. (D) Axon staining
 624 by N200. (E) Schwann cell staining by p75. (F) Axon and neuromuscular junction staining by
 625 N200 and α -Bungarotoxin. Dotted circle in panel F shows the position of neuromuscular
 626 junction. Mf = muscle fiber. Blue staining = DAPI. Bars = 100 μ m.

Table 1. Specific primers for mice.


No	Gene name (full name and/or typical role)	product size (bp)	Forward primer	Reverse primer	Utilization purpose
1	MyoD (myogenic regulatory factors)	184	GGCCACTCAGGTCTCAGG TGT	TGTTGCACTACACAGCATG CCT	Myogenic determination and differentiation markers
2	Myf5 (myogenic regulatory factors)	179	TTAGCAAACCATGAACACG AAACA	AAGGGGGCTTCATTACCA GG	
3	Pax7 (paired box transcription factors, also known as satellite cell marker)	192	CCCAACAGGTTTTCCCAAC TG	CGGCCTTCTTCTAGGTTCT GCT	
4	Pax3 (paired box transcription factors relate to embryonic muscle development)	256	TGGACAGTCTGCCACATC TCAGC	GGGAGCCTGTGCTGTAGC AATCAG	
5	Myogenin (myogenic regulatory factors)	262	TACGTCCATCGTGGACAGC AT	TCAGCTAAATCCCTCGCT GG	
6	c-met (hepatocyte growth factor receptor, which is present in quiescent satellite cell)	337	CCAAGCCGCGTATGTCAGT AAA	AATAAGTCGACGCGCTGCA	
7	M-cad (M-cadherin, a Ca ²⁺ -dependent cell adhesion molecule which is present in quiescent satellite cell)	193	GGGCTCTCTTTGGGATGT G	CTTCTGCACTCTGCCAGGA C	
8	MyH (skeletal muscle myosin heavy chain, cell differentiation marker)	152	TCAGGAAAGCCCAGCATG AG	TGCACCAGGAGGTCTTGCT C	
9	Desmin (Muscle relate intermediate filament protein, cell differentiation marker)	106	AGGGTCAGGACCGAGTTT GTG	GCCATGAGGGCAGTTTCA G	
10	IGF1 (Insulin-like growth factor-1)	185	CTGCTTGCTCACCTTCACC AG	TCCGGAAGCAACTCATC C	
11	NGF (Nerve growth factor, peripheral nerve growth and trophic factor)	106	TGCACCACGACTCACACCT TC	TCCTGCTGAGCACACACA CAC	Peripheral nerve growth and trophic factors

12	BDNF (Brain-derived neurotrophic factor)	582	GGGACTCTGGAGAGCGTG AAT	CCTTATGAATCGCCAGCCA AT	
13	GDNF (Glial cell-derived neurotrophic factor, peripheral nerve growth and trophic factor)	180	GTGAATCGGCCGAGACAA TG	CACACCGTTTAGCGGAATG C	
14	CNTF (Ciliary neurotrophic factor, peripheral nerve growth and trophic factor)	241	TTTCTGCCTTCGCCTACCA G	TTGGCCCCATAATGGCTCT C	
15	LIF (Leukemia inhibitory factor, peripheral nerve growth and trophic factor)	169	ATCGGATGGTCGCATACCT G	CCCACACGGTACTTGTGTGC AC	
16	Ninjurin (nerve injury-induced protein)	243	GGAGCAGGGCAATGATTTC G	GCCACGTCCATTACAGGCT TC	
17	Galectin-1 (Initial axonal growth regulator in peripheral nerves after axotomy)	109	TGTCTCAAAGTTCGGGGA GAGG	GGGCATTGAAGCGAGGAT TG	
18	Nestin (Nerve relate intermediate filament protein, cell differentiation marker)	233	GCTCTGGGCCAGCACTCTT AG	TGTAGACAGGCAGGGCTA GCA	
19	Sox10 (transcription factor relate to Schwann cell-development)	213	TCCCCATGTTCTTCCCATCC	CAAAGGGTGCAAGGCAAA GG	
20	VEGF (Vascular endothelial growth factor, vascular relating growth factor)	260	TCAGGGTTTCGGGAACCA GAC	TTCCGGGCTTGGCGATTTA G	Vascular relating growth factor
21	HGF (Hepatocyte growth factor, common elements to muscle and vascular growth)	169	TCAGCACCATCAAGGCAA GG	GATGGCACATCCACGACCA G	
22	PDGF-b (Platelet-derived growth factor-b, vascular relating growth factor)	271	AGCCAAGACGCCTCAAGC TC	GGGTGAGGGAAGCACCAT TG	
23	TGFb (Transforming growth factor-b, vascular relating growth factor)	195	CCAAGGGCTACCATGCCAA C	ACTGCTCCACCTTGGGCTT G	
24	EGF (Epidermal Growth Factor, common elements to muscle and nerve growth)	137	TGCGGATGGTACGAATGGT G	GTGGAATCCAGCAGCTTTG C	
25	FGF2 (basic fibroblast growth factor, common elements to muscle and nerve growth)	161	GCCAACCGGTACCTTGCTA TG	TGCCCAGTTCGTTTCAGTG C	
26	HPRT (hypoxanthine guanine phosphoribosyl transferase)	111	GCAAACCTTGTCTTCCCTG GTAAAG	CAACAAAGTCTGGCCTGTA TCCA	House-keeping control gene


627 Table 2. Functional assessment of the operated muscle

Experimental group		Short term (4-8 weeks) recovery group (n=4)		Long term (14-18 weeks) recovery group (n=4)	
		Muscle mass (mg)	Tetanic tension N (1×10^2)	Muscle mass (mg)	Tetanic tension N (1×10^2)
SP group (n=8)	Op-side	29.0±6.3	25.5±7.4	38.9±4.9	37.4±9.7
	Cont-side	45.2±5.8	71.1±15.8	50.4±0.5	75.8±11.8
	Recovery ratio	64%	36%	77%	49%
C group (n=5)	Op-side	unmeasurable	unmeasurable	nd	nd
	Cont-side	51.6±0.7	79.7±3.8	nd	nd
	Recovery ratio	0	0	nd	nd


628 Values are expressed average ±SE. *p<0.05 4-weeks vs. 10 weeks tetanus.



629 **Figure 1.** Macroscopic and schematic images of procedures used in MTJ complete rupture
 630 model preparation and sheet-pellet transplantation. Photographs of a left-TA muscle were taken.
 631 A = Step 1; B = Step 2; and C = Step 4. Dotted circle in B shows peeling of fibers. White arrows
 632 in C show partially sutured skin. Bars = 1 mm.




633 **Figure 2.** RT-PCR analysis of Sk-MSC sheet-pellet and its expressions of cytokines immediately
 634 prior to transplantation. (A) Expressions of myogenic, neurotrophic, and vasculogenic factor
 635 mRNAs was observed, confirming the quality of the sheet-pellet preparation. bp = base pair. (B)
 636 Several cytokines related to the muscle and vascular regeneration was also detected in the culture
 637 supernatant of the sheet-pellet, confirming the putative capacity of paracrine.




638 **Figure 3.** Differences of operated TA muscle mass and tetanic tension output between the short
 639 (4-8 weeks) and long (14-18 weeks) term groups, and these composed individual plots at each
 640 measurement point. Average of operated muscle mass (A) and tetanic tension output (B) were
 641 higher in the long term group (but not significant). (C and D) Linear relationships between term
 642 and recovery are detected on the individual plots of the long term group, but not in the short term
 643 group both in the muscle mass (C) and tetanic tension output (D).


After sheet-pellet transplantation




After media transplantation



644 **Figure 4.** Macroscopic observation of surgically treated TA muscles at 5-10 weeks after
 645 transplantation *in situ* and *in vitro* (after removal). Photographs were taken by synchronizing light
 646 conditions as the fluorescence + normal. (A-G) Typical features of sheet-pellet (GFP⁺)
 647 transplanted muscles. A-C = Pattern 1, D = Pattern 2, E = Pattern 3, F = Pattern 4, and G-H =
 648 Pattern 5. Arrows in B, D, E, F, G, and H show blood vessels. (I and J) Typical features of media
 649 transplanted control muscles. White arrows in panel I show the dent in the TA position. Red
 650 arrows in panel J show fat tissue. Black arrows in I and J indicate tibial bone. Bars = 1 mm.



651 **Figure 5.** Immunohistochemical detection of engrafted Sk-MSCs in cross-section (operated
 652 muscle from Pattern 1, 7 weeks after operation). (A and B) Relationship among the GFP⁺ cell-
 653 derived connective tissue, recipient tendon, and muscle fibers. Skeletal muscle fibers were
 654 stained with Sk-actin (skeletal muscle actin, A), and tendon and connective tissues were stained
 655 with Elastica Van Gieson (B). (C) Endothelial cell staining with CD31. (D) Axon staining with
 656 Neurofilament 200 (N200). (E) Schwann cell staining with p75. (F) Dystrophin staining for
 657 skeletal muscle fibers in the MTJ. Muscle fibers expressing dystrophin (red reactions). T =
 658 tendon. Dotted lines in D and E show the border between connective tissue and muscle fibers.
 659 Blue staining = DAPI. Bars in A and B = 200 μ m, C-E = 100 μ m.



660 **Figure 6.** Immunohistochemical detection of engrafted Sk-MSCs in longitudinal sections
 661 (operated muscle from Pattern 5, 8 weeks after operation). (A) Close relationship between donor-
 662 derived GFP⁺ connective tissue and muscle fibers was also apparent in the longitudinal images.
 663 (B) GFP⁺ muscle fibers were observed. (C) Vascular smooth muscle staining. (D) Axon staining
 664 by N200. (E) Schwann cell staining by p75. (F) Axon and neuromuscular junction staining by
 665 N200 and α -Bungarotoxin. Dotted circle in panel F shows the position of neuromuscular
 666 junction. Mf = muscle fiber. Blue staining = DAPI. Bars = 100 μ m.